Dr. Alison K. Conlin, MD

Dr. Conlin practices at Providence Portland Medical Center in Portland, Oregon, part of Providence Health & Services.

Dr. Conlin's NPI, 1841460193, was assigned on March 3, 2008. Dr. Conlin holds Oregon license MD248497.

Dr. Conlin's primary practice is Providence Portland Medical Center, at 4805 NE Glisan Street, Portland, OR 97213 in Multnomah County. The practice phone is (503) 215-1111.

Dr. Conlin's primary practice is Providence Portland Medical Center in Portland, Oregon, part of Providence Health & Services. Dr. Conlin is also affiliated with OHSU Hospital. The medical group on file is Providence Medical Group, Oregon. Dmand AI also links Dr. Conlin to 3 more hospitals, 7 medical groups, 1 group practice or clinic and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Conlin practices, 7 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Conlin's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Conlin's licenses on file in 2 states: Oregon and New York.

CMS data shows 568 Medicare services from Dr. Conlin across 5 procedure codes in 2024, for 141 Medicare patients. Medicare paid $30,550 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 141 Medicare patients who saw Dr. Conlin in 2024. The largest group is 65 to 74, with 68 patients. 75% of them have cancer, and 61% have high blood pressure. 9% are also on Medicaid. Their average risk score is 1.30, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Conlin's median patient age at 71, with 98% women.

In 2024, Dr. Conlin wrote 1,177 Medicare Part D claims for 235 patients. 90% of them were for generic drugs. CMS names the drug for 1,009 of them, across 26 drugs with 11 or more claims each, at $1,145,886 in total drug cost. In 2023, CMS named 920 claims across 18 drugs.

Dr. Conlin accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Conlin as offering telehealth.

Dmand AI links 31 papers to Dr. Conlin, published from 2012 to 2025. 2019 was the busiest year, with 5. The most frequent topics are Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Receptor, ErbB-2. Dr. Conlin has published most often in Clin Breast Cancer. Dr. Conlin's most frequent co-authors are Supriya Gupta Mohile, MD, Kah Poh Loh, MBCHB and Allison Marian Magnuson, DO.

Dmand AI links Dr. Conlin to 11 clinical trials, 4 of them phase 3 studies. 8 are still active or recruiting. Conditions studied include Breast Neoplasms, Carcinoma, Non-Small-Cell Lung and Breast Diseases. National Cancer Institute (NCI) sponsors the most, 8. Open Payments lists research payments to Dr. Conlin that name 1 trial.

CMS Open Payments shows 124 general payments to Dr. Conlin from 12 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 78% of the total. Seagen Inc. paid the most, $30,821. It also lists 7 research payments totaling $7,000 from 2018 to 2024, naming 1 clinical trial.